PKN2
| Official symbol: | PKN2 |
| Full name: | protein kinase N2 |
| Location: | 1p22.2 |
| Also known as: | PRKCL2, PRK2, STK7, Pak-2 |
| Entrez ID: | 5586 |
| Ensembl ID: | ENSG00000065243 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.44 |
|
|
|
| Recurrently deleted in 2 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
| Recurrently mutated in 1 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 3 |
|
|
| Fusions detected in 2 cancer type(s) |
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 103.65 (Percentile rank: 73.16%) |
| PubTator score: | 40.76 (Percentile rank: 64.57%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
